Multicenter Study Of Natalizumab Plus Standard Steroid Treatment For High Risk Acute Graft-Versus-Host Disease
Clinical trial NCT02133924 · COMPLETED
Trial details
- NCT number
- NCT02133924
- Sponsor
- John Levine
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2016-08-01
- Primary completion
- 2020-12-10
- Enrollment
- 76
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.